KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.Fertil SterilPMID 33814126无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.J UrolPMID 33818140无 PMCID2021-Aug0.85The record describes an indirect comparison (network meta-analysis) of multiple prior trials, not an original primary or key secondary report of a single randomized trial. The primary efficacy endpoint (metastasis-free survival) is a time-to-event outcome, but the analysis is a post-hoc adjusted comparison. The drug intervention is not clearly established as a single drug-containing arm within a trial being reported; the study compares multiple drugs across separate trials.待处理
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.Ann Rheum DisPMID 33827787PMC82926062021-Aug0.98未发现恶性肿瘤人群证据。待处理
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.J Thorac OncolPMID 33845211无 PMCID2021-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Future OncolPMID 33855868PMC93444362021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.Future OncolPMID 33858190无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.CephalalgiaPMID 33874756无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.Diabetes Obes MetabPMID 33881796无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.Clin TrialsPMID 33884929PMC82909822021-Aug0.90The study is a randomized phase 3 drug trial in oncology, but it evaluates pain measurement methodology as the primary endpoint, not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria for inclusion in the cohort.待处理
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.BreastPMID 33892316PMC80911752021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.Ann Rheum DisPMID 33906853PMC82925682021-Aug0.90Study is a Phase III randomized drug trial with original results, but it is not an oncology study (ankylosing spondylitis) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) as required for this oncology KM-digitization cohort.待处理
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.J Thorac OncolPMID 33915252无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.Ann OncolPMID 33932507无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinicaltrial.Int ImmunopharmacolPMID 33933848无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.Pediatr DiabetesPMID 33934456PMC83619702021-Aug0.98未发现恶性肿瘤人群证据。待处理
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).Ann Rheum DisPMID 33958326PMC82925662021-Aug0.98未发现恶性肿瘤人群证据。待处理
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.Acta OrthopPMID 33977825PMC83820182021-Aug0.85The record describes a Phase III randomized clinical trial of a drug (pexidartinib) for tenosynovial giant cell tumor (oncology). However, the primary/key efficacy endpoints reported are patient-reported outcomes (physical function and stiffness), not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint.待处理
A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.Gynecol OncolPMID 34016453无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.Epilepsy BehavPMID 34023810无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.OncologistPMID 34028126PMC83425912021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.Cancer SciPMID 34036692PMC83539422021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.Br J HaematolPMID 34046887无 PMCID2021-Aug0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.Lancet Respir MedPMID 34051877PMC81591932021-Aug0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.Respir MedPMID 34058682无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.Lancet Gastroenterol HepatolPMID 34087115无 PMCID2021-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A phase 3, open-label, controlled, randomized, multicenter trial evaluating the efficacy and safety of StrataGraft® construct in patients with deep partial-thickness thermal burns.BurnsPMID 34099322无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.Ann OncolPMID 34102253无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent.Mol Cancer TherPMID 34108261无 PMCID2021-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.Gynecol OncolPMID 34112513无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial.Dig Liver DisPMID 34112615无 PMCID2021-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.Neurourol UrodynPMID 34139038PMC83620472021-Aug0.98未发现恶性肿瘤人群证据。待处理
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.Breast Cancer Res TreatPMID 34148205PMC82727082021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.Lancet Gastroenterol HepatolPMID 34153231无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and safety of a live attenuated varicella vaccine in children 1-12 years of age: A randomized, blinded, controlled, non-inferiority phase 3 clinical trial.Contemp Clin TrialsPMID 34157417无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.Br J CancerPMID 34158598PMC84056162021-Aug0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.Lancet OncolPMID 34174189无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Senior WISE intervention: Gender differences in bodily pain and trait anxiety.Arch Psychiatr NursPMID 34176575PMC82392522021-Aug0.98未发现恶性肿瘤人群证据。待处理
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.Cancer MedPMID 34189869PMC83661002021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.Ann OncolPMID 34219000无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase II/III placebo-controlled randomized trial of safety and efficacy of growth hormone treatment in incomplete chronic traumatic spinal cord injury.Spinal CordPMID 34226654无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.Aliment Pharmacol TherPMID 34227708PMC83617332021-Aug0.98未发现恶性肿瘤人群证据。待处理
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet OncolPMID 34237250无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.Lancet OncolPMID 34252374无 PMCID2021-Aug1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.Eur J CancerPMID 34256319无 PMCID2021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
[Not Available].Aktuelle UrolPMID 34318458无 PMCID2021-Aug0.45Metadata confirms oncology, human, randomized, Phase III. However, the abstract is empty and deterministic review found no reliable time-to-event signal or drug intervention signal. Cannot establish eligibility without explicit confirmation of a drug-containing intervention and a primary/key secondary time-to-event endpoint from the original report.待处理
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study.Clin TherPMID 34332788无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.EBioMedicinePMID 34333237PMC83401252021-Aug0.70The record is eligible for oncology, human, randomized, phase 3, and time-to-event, but the drug intervention is not explicitly described or evaluated in this report (it's a biomarker sub-study). Therefore, it does not meet the inclusion criteria for a primary drug-efficacy report.待处理
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.ESMO OpenPMID 34371381PMC83584162021-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Practice nurse-supported weight self-management delivered within the national child immunisation programme for postnatal women: a feasibility cluster RCT.Health Technol AssessPMID 34382932无 PMCID2021-Aug0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.RMD OpenPMID 34385364PMC83627172021-Aug0.98未发现恶性肿瘤人群证据。待处理